KWAR 23 

KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research^[1].

Human IgG4 kappa

Human IgG4 (S228P) kappa, Isotype Control

Human

SIRPα

KWAR 23 (0-1 μM; 4 h) shows antitumor activity of human neutrophil and macrophage^[1].
KWAR 23 induces human macrophage-dependent phagocytosis in human tumor-derived cell lines^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KWAR23 (intraperitoneal injection; 10 mg/kg; every other day; 21 d) exhibits effective antitumor activity in a human SIRPA knockin mouse model^[1].
KWAR23 enhances neutrophil and macrophage antitumor activity in SRG Mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

140885  [NCBI]

P78324

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

143.4 kDa

2243227-60-1

Liquid

Colorless to light yellow

[KWAR 23]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG4 kappa

• 
  Immobilized SIRP alpha/CD172a Protein, Human can bind KWAR 23. The EC₅₀ for this effect is 5.3 ng/mL.
• 
  Flow Cytometry analysis of U937 cells labelling SIRPα (red) with KWAR 23 (anti-SIRPα) (HY-P99175). Goat Anti-Human IgG (Alexa Fluor 488) (HY-P83776) at a dilution of 1/1000 was used as the secondary antibody. Blue-Human IgG4 kappa (HY-P99003). Black-Unlabelled control, cells without incubation with primary antibody.

• [1]. Ring NG, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578-E10585.  [Content Brief]